Role of Real-World Evidence in Decision Making Roundtable
About the Role of Real-World Evidence in Decision Making Roundtable
12 December 2016
On December 12th, 2016, the Institute of Health Economics (IHE) held a roundtable discussion regarding the role of real-world evidence (RWE) in decision-making in Canada, with a focus on RWE generated for pricing and reimbursement.
Download Summary Report
Real-world evidence: What role can it play in real-world decision making? Summary Report
The meeting brought together 11 representatives of key stakeholders: experts in evidence assessment, payers, and those generating RWE including academia and industry. The purpose of the meeting was to discuss preferences and perceptions of the use of RWE for pricing and reimbursement of new medicines in Canada and what more may be needed to ensure its optimal use. This roundtable served as a forum to identify key points of discussion and highlights gaps and opportunities for further discussion in the future with a broader group of stakeholders. The proposed actions and next steps in this document are not a consensus recommendation by roundtable participants, but should be considered an accurate reflection of the discussion.
The focus of the roundtable discussion was to capture preferences and perceptions of the use of RWE for new medicine decisions in Canada. The use of RWE post-marketing or for conditional reimbursement was outside of the scope of the discussion. The following questions were addressed during the discussion:
- What is the state of system readiness in the Canadian health system and current approaches to RWE in drug reimbursement decisions in Canada and internationally?
- Is guidance for the use of RWE in pricing and reimbursement decisions desirable and feasible?
- What approaches or next steps might be taken to developing and implementing guidance or other tools to promote the consistent use of RWE?
- Real World Evidence Roundtable (2 November 2014)